Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...
Vigil Neuroscience advances VG-3927, a small molecule TREM2 agonist, into Phase II Alzheimer’s trials in Q3 2025 following ...
Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback